Since CGRP and SP are two important neuropeptides in the pathophysiological process of cutaneous neurogenic inflammation, it was hypothesized that BoNT-A can potentially be used for treating several inflammatory skin diseases, including psoriasis [46,47,48]. The gene discussed is CALCA; the disease is psoriasis.